Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML.
Silva H, Martin G, Birocchi F, Wehrli M, Kann MC, Supper VM, Parker A, Graham CE, Bratt AG, Bouffard AA, Donner H, Escobar G, Takei HN, Armstrong A, Goncalves S, Berger TR, Choi BD, Maus MV, Leick MB. Silva H, et al. Among authors: leick mb. Blood. 2024 Nov 21:blood.2023023210. doi: 10.1182/blood.2023023210. Online ahead of print. Blood. 2024. PMID: 39571145
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KME, Frigault MJ, Maus MV. Bailey SR, et al. Among authors: leick mb. Blood Cancer Discov. 2022 Mar 1;3(2):136-153. doi: 10.1158/2643-3230.BCD-21-0181. Blood Cancer Discov. 2022. PMID: 35015685 Free PMC article.
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala NJ, Wehrli M, Lee WH, Parker AL, Wiggin HR, Bouffard A, Dey A, Leick MB, Katsis K, Elder EL, Dolaher MA, Cook DT, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KME, Maus MV. Frigault MJ, et al. Among authors: leick mb. Blood. 2024 Sep 12;144(11):1153-1167. doi: 10.1182/blood.2024024104. Blood. 2024. PMID: 38781564 Clinical Trial.
CAR-T cells beyond CD19, UnCAR-Ted territory.
Leick MB, Maus MV. Leick MB, et al. Am J Hematol. 2019 May;94(S1):S34-S41. doi: 10.1002/ajh.25398. Epub 2019 Jan 23. Am J Hematol. 2019. PMID: 30632631 Free article. Review.
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Frigault MJ, et al. Blood. 2019 Sep 12;134(11):860-866. doi: 10.1182/blood.2019001694. Epub 2019 Jul 18. Blood. 2019. PMID: 31320380 Free PMC article.
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. Choi BD, et al. Among authors: leick mb. Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22. Nat Biotechnol. 2019. PMID: 31332324
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Schmidts A, et al. Among authors: leick mb. J Immunother Cancer. 2020 Sep;8(2):e000990. doi: 10.1136/jitc-2020-000990. J Immunother Cancer. 2020. PMID: 32900862 Free PMC article.
44 results